🏭 Peptide CDMO Market Landscape Deep Analysis
Report ID: MKI-CDMO-2026-001 | Release Date: July 2026
Coverage: Global and China peptide CDMO market, capacity comparison, technical capabilities
1. Market Overview
The global peptide CDMO (Contract Development and Manufacturing Organization) market reached approximately $3.2B in 2024, representing 10.5% year-over-year growth. Chinese CDMO enterprises have rapidly increased their market share from 18% in 2020 to 32% in 2024, with projections reaching 45% by 2028.
CDMO Market Core Drivers
- GLP-1 drug API capacity insufficiency driving increased large pharma CDMO outsourcing ratios
- Startup biotechs relying on CDMOs to bridge the gap from R&D to commercialization
- Chinese CDMO cost advantage (approximately 50-60% of European levels)
- Peptide generic drug companies requiring specialized CDMO support for API production
2. Global CDMO Market Structure
2.1 By Service Type (2024)
| Service Type |
Market Size ($B) |
Share |
Growth Rate |
| API Manufacturing |
$1.7 |
53% |
+12% |
| Formulation Development and Manufacturing |
$0.8 |
25% |
+9% |
| Early-Stage R&D Services |
$0.4 |
13% |
+8% |
| Analytical and Quality Control |
$0.3 |
9% |
+7% |
2.2 By Customer Type
| Customer Type |
CDMO Revenue Share |
Core Needs |
| Large Pharma (Novo/Lilly, etc.) |
45% |
Commercial API contract manufacturing, capacity supplementation |
| Mid-Sized Biotechs |
28% |
Clinical-stage CDMO, technology transfer |
| Generic Pharma |
22% |
Generic API development, cost optimization |
| Academic/Startups |
5% |
Early-stage R&D support |
3. Core CDMO Enterprise Capacity and Technical Capability Comparison
3.1 Comprehensive Capability Comparison
| Company |
Country |
2024 Peptide CDMO Revenue |
Peptide Capacity |
Core Technology |
cGMP Certification |
Differentiating Advantage |
| WuXi AppTec (WuXi TIDES) |
China |
¥5.8B ($0.8B) |
40,000L SPPS |
SPPS+LPPS+Continuous Flow |
FDA/EMA/NMPA |
World's largest integrated CRDMO |
| Sinopeptide |
China |
¥2.8B ($0.39B) |
2,000 kg/yr SS |
SPPS |
FDA/NMPA |
GLP-1 API cost leader |
| Asymchem |
China |
¥1.2B ($0.17B) |
5,000L |
SPPS+Continuous Flow |
FDA/NMPA |
Continuous flow synthesis technology leader |
| Shengnuo Biotechnology |
China |
¥0.8B ($0.11B) |
1,000 kg/yr |
SPPS+Purification |
NMPA |
Generics + CDMO dual model |
| Jiuzhou Pharma |
China |
¥0.6B ($0.08B) |
Expanding |
SPPS+Fermentation |
NMPA |
Peptide + small molecule dual platform |
| Bachem |
Switzerland |
$0.55B |
3,000L+ |
SPPS+LPPS |
FDA/EMA |
Europe's largest peptide CDMO |
| Lonza |
Switzerland |
$0.45B |
4,000L |
LPPS |
FDA/EMA |
Biologics CDMO extension |
| PolyPeptide |
Switzerland |
$0.35B |
3,000L |
SPPS+LPPS |
FDA/EMA |
Established peptide CDMO |
3.2 Technical Capability Deep Assessment
| Technical Capability |
WuXi AppTec |
Sinopeptide |
Asymchem |
Bachem |
Lonza |
| Solid-Phase Synthesis (SPPS) |
★★★★★ |
★★★★★ |
★★★★☆ |
★★★★★ |
★★★☆☆ |
| Liquid-Phase Synthesis (LPPS) |
★★★★★ |
★★★☆☆ |
★★★★☆ |
★★★★★ |
★★★★★ |
| Continuous Flow Synthesis |
★★★★★ |
★★★☆☆ |
★★★★★ |
★★★★☆ |
★★★☆☆ |
| Fragment Condensation |
★★★★★ |
★★★★☆ |
★★★★☆ |
★★★★★ |
★★★★☆ |
| Macrocyclic Peptide Technology |
★★★★☆ |
★★★☆☆ |
★★★☆☆ |
★★★★☆ |
★★★★☆ |
| Injectable Filling |
★★★★★ |
★★★★☆ |
★★★☆☆ |
★★★★★ |
★★★★★ |
| Oral Formulation Development |
★★★★☆ |
★★★☆☆ |
★★★★☆ |
★★★★☆ |
★★★★☆ |
| EPA/DPA Impurity Control |
★★★★★ |
★★★★☆ |
★★★★☆ |
★★★★★ |
★★★★★ |
| Analytical Method Development |
★★★★★ |
★★★★☆ |
★★★★☆ |
★★★★★ |
★★★★☆ |
| Regulatory Filing Support |
★★★★★ |
★★★★☆ |
★★★★☆ |
★★★★★ |
★★★★★ |
4. Chinese CDMO Enterprise Deep Analysis
4.1 WuXi AppTec (WuXi TIDES)
| Metric |
Data |
| 2024 Revenue |
¥5.8B (peptide + oligonucleotide TIDES business) |
| Employees |
2,000+ (peptide division) |
| Capacity Expansion Plan |
40,000L → 60,000L (2026) |
| Core Customers |
15 of top 20 global pharma are TIDES customers |
| Technology Moat |
Continuous flow SPPS, ultra-large-scale purification, automation |
Competitive Advantages:
- Integrated CRDMO: One-stop service from sequence design to commercial API + formulation
- Scale economics: World's largest peptide solid-phase synthesis capacity, strong cost control
- Customer lock-in: Long-term collaboration frameworks with Novo, Lilly, etc.
4.2 Sinopeptide
| Metric |
Data |
| 2024 Revenue |
¥2.8B (primarily peptides) |
| Capacity |
2,000 kg/yr (expanding to 4,000 kg in 2024) |
| Core Products |
Semaglutide API, Tirzepatide API, cosmetic peptides |
| Capacity Utilization |
95%+ |
Competitive Advantages:
- Leading GLP-1 API synthesis route optimization capability, cost below WuXi AppTec
- API export qualification with both China NMPA + US FDA certification
- Competitive pricing for generic APIs (liraglutide, etc.)
4.3 Asymchem
| Metric |
Data |
| 2024 Revenue |
¥1.2B (peptide business) |
| Core Capability |
Continuous flow peptide synthesis technology |
| Customers |
Primarily overseas innovative pharma companies |
| Strategy |
Peptide + small molecule + biologics triple platform |
Competitive Advantages:
- Continuous Flow SPPS technology leading in China, synthesis time reduced by 70%
- Rich overseas customer resources including multiple US biotechs
4.4 Shengnuo Biotechnology
| Metric |
Data |
| 2024 Revenue |
¥0.8B |
| Core Model |
"Generics + CDMO" dual-engine driven |
| Capacity |
1,000 kg/yr |
| Specialization |
Peptide injectable generics + CDMO |
4.5 Jiuzhou Pharma
| Metric |
Data |
| 2024 Revenue |
¥0.6B (peptide business, rapidly growing) |
| Capacity |
New capacity under construction |
| Strategy |
Extending from small molecule CDMO to peptides |
| Characteristics |
Peptide + small molecule + fermentation triple technology platform |
5. Pricing Trends and Cost Analysis
5.1 CDMO Service Price Trends
| Service Type |
2024 Price Range |
2026E Price Trend |
China vs Overseas Price Ratio |
| Early R&D (mg~g scale) |
¥10,000-50,000/sequence |
Stable |
China 50-60% of overseas |
| Clinical API (g~kg scale) |
¥50,000-200,000/kg |
Slightly rising |
China 55-65% of overseas |
| Commercial API (kg scale) |
¥30,000-150,000/kg |
Slightly declining |
China 50-60% of overseas |
| Formulation (injectable) |
¥5-20/unit (commercial) |
Stable |
China 40-50% of overseas |
5.2 Sources of Chinese CDMO Cost Advantage
| Cost Item |
China |
Europe/US |
Variance |
| Labor cost |
$15-30/hour |
$50-80/hour |
China 40-60% lower |
| Facility construction |
¥5,000-8,000/m² |
€2,000-4,000/m² |
China 50-60% lower |
| Environmental compliance |
¥50-100/g raw material |
€100-200/g raw material |
China lower |
| Raw material domestication |
Highly domesticated |
Import-dependent |
China more cost-advantageous |
| Electricity/water/energy |
Lower |
Higher |
China 30-40% lower |
6. Quality Systems and Compliance Standards
6.1 Domestic and International GMP Standard Comparison
| Standard Item |
China NMPA GMP |
US FDA cGMP |
EU EMA GMP |
| Peptide Synthesis Workshop |
Independent HVAC + Grading |
Equivalent |
Equivalent |
| EPA/DPA Control |
Guidelines issued |
Very strict |
Relatively strict |
| Genotoxic Impurities |
ICH M7 |
Equivalent |
Equivalent |
| Analytical Validation |
Refer to Pharmacopoeia + ICH |
Equivalent |
Equivalent |
| Stability Studies |
ICH Q1A |
Equivalent |
Equivalent |
7. CDMO Market Trends and Outlook (2025-2030)
7.1 Key Trends
- Capacity Arms Race: 2024-2026 global peptide CDMO capacity will double, with leader capacity moving toward 100,000L+
- Vertical Integration: CDMOs extending toward "API + formulation + early R&D" full chain to enhance customer stickiness
- Technology Barrier: Continuous flow synthesis and AI-assisted process optimization will become competitive thresholds for next-generation CDMOs
- Chinese CDMO Globalization: WuXi AppTec and other Chinese companies accelerating overseas capacity deployment (Singapore/US bases)
- Generic CDMO Demand Explosion: 2026-2028 GLP-1 generic drugs launching intensively, driving surging CDMO demand from generic pharma
7.2 Market Size Forecast
| Year |
Global Peptide CDMO Market ($B) |
China CDMO Share |
China CDMO Revenue ($B) |
| 2024 |
$3.2 |
32% |
$1.02 |
| 2025E |
$3.6 |
35% |
$1.26 |
| 2026E |
$4.1 |
38% |
$1.56 |
| 2028E |
$5.2 |
42% |
$2.18 |
| 2030E |
$6.5 |
45% |
$2.93 |
Conclusion
The global peptide CDMO market is in a period of high growth. Chinese CDMO companies are transitioning from "followers" to "leaders" by leveraging cost advantages, capacity expansion speed, and continuously upgrading technical capabilities. WuXi AppTec has established itself as the world's largest peptide CDMO, while Sinopeptide holds a significant cost advantage in GLP-1 APIs. For downstream pharma companies, selecting a CDMO partner with continuous flow technology, full-chain capabilities, and international compliance qualifications is key to winning in the GLP-1 wave.
Data Sources
Data compiled from 2024 annual reports of respective companies, industry research reports (Grand View Research, Frost & Sullivan), and company public information.
View SENO Biotechnology CDMO Capacity Details → Visit SENO CDMO Services. SENO Biotechnology provides professional peptide CDMO services covering the full process from solid-phase synthesis, purification, QC analysis to formulation development, with cGMP standards ensuring quality. Contact us for detailed service solutions and pricing.